Research Progress Of CDK4/6 Inhibitors In HR+,HER2-advanced Breast Cancer

In the comprehensive treatment of breast cancer,hormone receptor positive(HR+)breast cancer accounts for about 75% of all types of breast cancer,endocrine therapy is one of its effective treatment methods.However,its effectiveness is limited by primary resistance and acquired resistance.As the emergence of cyclin-dependent protein kinase(CDKs)inhibitors and their associated clinical trials show that for HR +,human epidermal growth factor receptor 2 negative(Her2-),the CDK4/6 inhibitor is a effective drug that reverses the resistance of endocrine therapy and shows clear advantages in disease-free survival.CDKs are a group of serine/threonine protein kinases that act synergistically with cyclins and are important factors in cell cycle regulation.Unregulated proliferation of normal cells can lead to unrestricted cell growth and proliferation.This review describes the efficacy,safety,and pharmacokinetics of three selective CDK4/6 inhibitors(Palbociclib,Ribociclib,and Abemaciclib)in clinical trials of HR+,HER2-advanced breast cancer.This article also reviews CDK4/6 Inhibitors can stimulate immune response and may block the distant metastasis of triple-negative breast cancer(TNBC)cell lines and other related latest research results.We hope to provide reference for related cancer treatment research with CDK4/6 inhibitors.